share_log

8-K: Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

8-K: Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

8-K：梯瓦公佈2024年第三季度強勁的財務業績，由仿製藥業績和創新投資組合增長帶動；上調了2024年財務展望，包括收入、調整後的息稅折舊攤銷前利潤和非公認會計准則每股收益
美股SEC公告 ·  2024/11/06 20:02

Moomoo AI 已提取核心訊息

Teva Pharmaceutical reported robust Q3 2024 results with revenues reaching $4.3 billion, up 15% in local currency terms year-over-year. The growth was driven by strong performance in generics across all regions and innovative portfolio expansion. AUSTEDO revenues surged 28% to $435 million, while AJOVY global revenues grew 21% to $137 million.The company demonstrated solid operational execution with non-GAAP operating margin improving to 28.0% from 26.5% in Q3 2023. Free cash flow generation was strong at $922 million, compared to $229 million in the prior year period. The generics business showed remarkable growth, increasing by 30% in the U.S., 8% in Europe, and 13% in International Markets in local currency terms.Based on the strong performance, Teva raised its full-year 2024 guidance, now expecting revenues of $16.1-16.5 billion, adjusted EBITDA of $4.7-5.0 billion, and non-GAAP EPS of $2.40-2.50. The company remains on track with its strategic initiatives, including the planned divestiture of its API business targeted for completion in first half of 2025.
Teva Pharmaceutical reported robust Q3 2024 results with revenues reaching $4.3 billion, up 15% in local currency terms year-over-year. The growth was driven by strong performance in generics across all regions and innovative portfolio expansion. AUSTEDO revenues surged 28% to $435 million, while AJOVY global revenues grew 21% to $137 million.The company demonstrated solid operational execution with non-GAAP operating margin improving to 28.0% from 26.5% in Q3 2023. Free cash flow generation was strong at $922 million, compared to $229 million in the prior year period. The generics business showed remarkable growth, increasing by 30% in the U.S., 8% in Europe, and 13% in International Markets in local currency terms.Based on the strong performance, Teva raised its full-year 2024 guidance, now expecting revenues of $16.1-16.5 billion, adjusted EBITDA of $4.7-5.0 billion, and non-GAAP EPS of $2.40-2.50. The company remains on track with its strategic initiatives, including the planned divestiture of its API business targeted for completion in first half of 2025.
Teva 藥品發佈了強勁的2024年第三季度業績，收入達到43億，同比增長15%（以當地貨幣計）。增長源於各地區仿製藥的強勁表現和創新產品組合的擴展。AUSTEDO 的收入飆升28%，達到43500萬，而AJOVY的全球收入增長21%，達到13700萬。該公司展現了穩健的運營執行力，非公認會計准則的營業利潤率從2023年第三季度的26.5%提升至28.0%。自由現金流強勁，達到92200萬，而去年同期爲22900萬。仿製藥業務表現出色，在美國增長了30%，在歐洲增長8%，在國際市場增長13%（以當地貨幣計）。基於強勁的業績，Teva上調了2024年全年的指引，預計收入爲161億到165億，調整後的EBITDA爲47億到50億，非公認會計准則的每股收益爲2.40到2.50。該公司在實現其戰略目標的道路上保持順利，包括計劃在2025年上半年完成其API業務的剝離。
Teva 藥品發佈了強勁的2024年第三季度業績，收入達到43億，同比增長15%（以當地貨幣計）。增長源於各地區仿製藥的強勁表現和創新產品組合的擴展。AUSTEDO 的收入飆升28%，達到43500萬，而AJOVY的全球收入增長21%，達到13700萬。該公司展現了穩健的運營執行力，非公認會計准則的營業利潤率從2023年第三季度的26.5%提升至28.0%。自由現金流強勁，達到92200萬，而去年同期爲22900萬。仿製藥業務表現出色，在美國增長了30%，在歐洲增長8%，在國際市場增長13%（以當地貨幣計）。基於強勁的業績，Teva上調了2024年全年的指引，預計收入爲161億到165億，調整後的EBITDA爲47億到50億，非公認會計准則的每股收益爲2.40到2.50。該公司在實現其戰略目標的道路上保持順利，包括計劃在2025年上半年完成其API業務的剝離。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Citius Oncology
    CTOR
    -- 0.930
    腦再生科技
    RGC
    -- 31.880
    正業生物
    ZYBT
    -- 5.380
    Emergent BioSolutions
    EBS
    -- 4.860
    Ironwood醫藥
    IRWD
    -- 1.470
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日